Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Sterke toename vraag "fully liquid"QUINVAXEM

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Sterke toename vraag "fully liquid"QUINVAXEM

102 Posts
Pagina: «« 1 2 3 4 5 6 »» | Laatste | Omlaag ↓
  1. [verwijderd] 27 december 2008 20:41
    quote:

    bilbo3 schreef:

    ...
    2008Q4 is het beste kwartaal tot nu toe met ruim 10 miljoen vaccins quinvaxem geleverd. (vergelijk eens 2007 met in totaal 12.730 vaccins.
    Beste bilbo3,

    Kan je aangeven hoeveel quinvaxem vaccins in 2009 geleverd moeten worden.

    Heeft iemand een indicatie hoeveel omzet van Unicef /WHO in 2009 valt (misschien enigszins door hepatitus B verkoop vervuilend).

    En/of gokjes ten aanzien van de omzet over 2009?

    Tnx
  2. flosz 20 januari 2009 12:52
    quote:

    bilbo3 schreef:

    Unicef heeft de leveringen tot en met 24 december weer bijgewerkt.
    Blijkbaar worden ruim 2,8 miljoen eenheden pas ontvangen door de donorlanden in januari 2009. Wellicht is dit voor Crucell toch al omzet 2008, maar voorzichtigheidshalve in het staatje niet meegenomen. 2008Q4 is het beste kwartaal tot nu toe met ruim 10.000 miljoen vaccins quinvaxem geleverd. (vergelijk eens 2007 met in totaal 12.730 vaccins.

    Even plakken.
    www.iex.nl/forum/topic.asp?forum=228&...
  3. [verwijderd] 20 januari 2009 21:49
    quote:

    maxen schreef:

    [quote=bilbo3]
    ...
    2008Q4 is het beste kwartaal tot nu toe met ruim 10.000 miljoen vaccins quinvaxem geleverd. (vergelijk eens 2007 met in totaal 12.730 vaccins.
    [/quote]
    Dank Bilbo voor deze update.
    Hier komt ie met de goede getallen (juiste aantal nullen):

    2008Q4 is het beste kwartaal tot nu toe met ruim 10 miljoen (10.110.000) vaccins quinvaxem geleverd. (vergelijk eens met HEEL 2007 met 12,7 miljoen vaccins (12.730.000).

    Totaal voor 2008 is 33,3 miljoen (33.322.000) vaccins.
    Hmm....even een scherp mes pakken en daar kort door de bocht mee gaande, komt men op basis van groei voor Quinvaxem:

    Over 2008:
    Heel grof heeft Crucell ca 33 mio dosis Quinvaxem geleverd hetgeen een percentage is van boven de 50%.
    (Hierbij tevens vanuit gegaan dat de groei in penta vaccins deels ten koste gaat van de HepB vaccin en weer gecompenseerd wordt door de leveringen aan China. Derhalve netto 0 impact aangenomen)
    Voor 2009 wordt een totaal aantal dosissen van 138 + 45 = 183 mio dosissen verwacht; dit met meerdere intredende marktpartijen (nu 4).
    Doordat de Koreaanse Won in het 4e kwartaal sterker gedaald is, kan Crucell scherper de onderhandelingen ingaan. Aanvullend pluspunt is de beperktere aantal vervolg dosissen benodigd bij Quinvaxem (ten opzichte van de 10 dosissen van sommige concurrenten).

    Derhalve geschat een reductie van het totale marktsegment van boven de 50% naar een 35%
    Resulteert in 64 mio dosissen oftewel bijna een verdubbeling (31 mio dosissen) ten opzichte van 2008.
    31 mio x $ 3,40 x 40% marge (deels door optimalisatie fabriek) / 1,30 (koers EUR) / uitstaande aandelen = bijna 0,50 Euro per aandeel extra bijdrage enkel dankzij groei van Quinvaxem aan de winst per aandeel.

    Klinkt niet slecht met het huidig beurklimaat.
    Bijlage:
  4. [verwijderd] 20 januari 2009 22:57
    Voor 2009 zijn reeds orders geplaatst door Unicef ter waarde van $270 mln (140+130)tegen eengemiddelde prijs zoals aangegeven door Unicef van ongeveer $3,41 dus ongeveer 80 mln doses. De nieuwe tender die in juni toegekend zal worden gaat
    over leveringen gedurende de periode 2010-2011-2012.
  5. [verwijderd] 21 januari 2009 00:52
    quote:

    nederbelg schreef:

    Voor 2009 zijn reeds orders geplaatst door Unicef ter waarde van $270 mln (140+130)tegen eengemiddelde prijs zoals aangegeven door Unicef van ongeveer $3,41 dus ongeveer 80 mln doses. De nieuwe tender die in juni toegekend zal worden gaat
    over leveringen gedurende de periode 2010-2011-2012.
    Tnx nederbelg,

    Maar dat resulteert direct in een hogere bijdrage van Quinvaxem aan de 2009 cijfers.
    Afhankelijk van de gekozen kw impliceert direct dat het huidige koersniveau (ca 1/2 tot 1 jaar op de vooruitlopende waarde) te laag staat.
    Quinvaxem levert al zo'n bijdrage aan de 2009 "virtuele winst" dat het huidig koersniveau vraagtekens oplevert.

    Crucell kan over 2009 een hogere winst boeken dan "slechts" 1 Euro per aandeel.
    De kw factor mag de belegger zelf bepalen.
  6. [verwijderd] 21 januari 2009 07:17
    quote:

    MeawandMoo1 schreef:

    [quote=nederbelg]
    Voor 2009 zijn reeds orders geplaatst door Unicef ter waarde van $270 mln (140+130)tegen eengemiddelde prijs zoals aangegeven door Unicef van ongeveer $3,41 dus ongeveer 80 mln doses. De nieuwe tender die in juni toegekend zal worden gaat
    over leveringen gedurende de periode 2010-2011-2012.
    [/quote]
    Tnx nederbelg,

    Maar dat resulteert direct in een hogere bijdrage van Quinvaxem aan de 2009 cijfers.
    Afhankelijk van de gekozen kw impliceert direct dat het huidige koersniveau (ca 1/2 tot 1 jaar op de vooruitlopende waarde) te laag staat.
    Quinvaxem levert al zo'n bijdrage aan de 2009 "virtuele winst" dat het huidig koersniveau vraagtekens oplevert.

    Crucell kan over 2009 een hogere winst boeken dan "slechts" 1 Euro per aandeel.
    De kw factor mag de belegger zelf bepalen.
    Helemaal mee eens. Rekening houdende met het feit dat door compensabele verliezen we hier spreken van een winst na belastingen en de toekomstige waarde van de pijplijn zou de koers nu al in de buurt van Euro 25 moeten liggen. Daarom is elk bod
    onder de Euro 35 een lachertje te noemen.
  7. [verwijderd] 25 januari 2009 02:59
    quote:

    nederbelg schreef:

    Helemaal mee eens. Rekening houdende met het feit dat door compensabele verliezen we hier spreken van een winst na belastingen en de toekomstige waarde van de pijplijn zou de koers nu al in de buurt van Euro 25 moeten liggen. Daarom is elk bod
    onder de Euro 35 een lachertje te noemen.
    Nog even als extra aanvulling vanuit de Hib Initiative.

    # Supplier capacity for all-liquid pentavalent demand is sufficient – manufacturers will need to ramp up production.

    # Suppliers will need to expand production to meet increased demand of liquid pentavalent

    Verwachte vraag vanaf 2013: 300 miljoen dossis
    (zie bijlage)
    Bijlage:
  8. [verwijderd] 25 januari 2009 10:00
    Gelet op het aantal suppliers dat nu WHO-proof is - 2, waarvan 1 de komende jaren de handen vol heeft aan de eigen indiase markt - is het op basis van het plaatje van MeawandMoo aannemelijk dat crxl in 4 jaar van een circa 60 mm doses naar 100 mm doses gaat van de GAVI-demand. 100 is circa 40% van de WHO-capacity. Met wat prijserosie en een"stabiele" €/$ is dan een omzetbodem van € 160 mm naar € 250 mm vanaf 2012. Oftewel in 2012 bijna €4 per aandeel!
  9. flosz 2 februari 2009 10:30
    어느 중소 벤처의 성공 사례를 이야기하는 것이 아니다......
    O.a. over kwinbaksem van keurusel enzo………

    Title [New Year Special] Bernays, the pharmaceutical industry, 'dark horse' to the emerging / [Yakup Shinmoon] January 7, 2009
    multinational pharmaceutical companies in 2009 rising to the 'Preview' - ② Verna bayiohtek Korea
    Manager Date 09-01-15 12:08

    View Series 2009 series of multi-national pharmaceutical companies and multinational pharmaceutical companies in 2009 expected to ... the second series' Verna bayiohtek Korea 'activities and future activities of the 2008 interview about sitneunda CEO. Verna in 2007 through sales and operating profit surges, domestic half of the multinational pharmaceutical companies are emerging as new powerhouses. In 2007 to exceed one hundred billion in revenue in 2008 to achieve sales of a multinational pharmaceutical company is at the brink of entering the top 10 ranking.
    2007 sales up 96.8 percent, 807 percent profit growth. One small success story is not to venture. Dutch biotechnology company keurusel (Crucell) 'of the domestic subsidiary, Verna bayiohtek Korea (the Verna) is a business performance in 2007. '1 Billion in 2008 exports of Verna's Top 100 billion won and sales across the state already high (96.4 billion revenue in 2007) is. Seen remarkable growth in recent years, Verna achieved a driving force juryeokpummokin 5 honhapbaek 'kwinbaksem (Quinvaxem ®)' in 2006, including 10 in the UN and international health organizations are beginning to supply. What made you think the success geupjakseureon one big item, but the actual presence in the domestic Verna and I look back upon the business' ready 'companies' natural' tadanghae success is more to see. Verna, launched in 1999 as a subsidiary of noksipja after, 2000 Netherlands' Rhein Biotech Group 'of the investment and the growth has been. After suffering several years of difficulties, but in February 2006 the Dutch biotechnology company keurusel to the merger, the Verna is a springboard for growth. The multinational pharmaceutical companies because of the productivity situation cheolsuha factory in Korea, Verna investment in South Korea has continued to perform. Steady improvement, and cutting-edge technology investments Verna yieojyeotgo to build production facilities, which play a decisive role in the success of the end of Verna said. The main items Bernardo in 2008, the kwinbaksemeul continued sales of the wit and will be adding new items and plans to promote the domestic release.

    Verna, Korea 168000000000 investment in seven years [bayiohtek Korea ansangjeom Bernardo, president of the interview]
    Q. Abroad through our investment in plant and focus on building a multinational pharmaceutical companies in Korea and Verna bayiohtek believe in it's new model? A. Tell us why the productivity of the multinational pharmaceutical companies with factories in Korea, the situation in the Verna bayiohtek continued to invest in Korea contributed to the development of the domestic pharmaceutical industry and biotechnology. The keurusel 'headquarters offices from the profit for all of South Korea in South Korea to build vaccine development and production facilities in seven years in the form of reinvestment amount of the investment goes to ₩ 168,000,000,000. Bayiohtek Verna Korea, with which, recombinant yeast Culture and purification technology, pharmaceutical technology, such as large honhapbaeksin proven advanced technology and workforce to 210 people, and in 2001 built a global level, the level of the quality system and Korea's IT infrastructure through quality of Verna bayiohtek Korea, Technology our competitiveness is the driving force can lead from the investment.

    Q. Market research and development plan or the new 2009 plan are you? A. Bernard Holland of The Korea bayiohtek bonsain 'keurusel' in step 100 in a variety of clinical research can occur. Of tuberculosis, malaria, rabies vaccine, including research and product pipeline, ongoing competitive market is the yesangdoe. Our level of innovation (Innovation & Discovery) effort for the qualified personnel and advanced production facilities, advanced facilities and know-how of Bernard bayiohtek Korea 'product commercialization, will lead to. Q. The goal of sales growth this year bayiohtek Verna? A. The first desk, the company does not tell you about the exact sales yesangaek widely awesome and we appreciate your patience, please. Korea's exports of bayiohtek Verna sales accounted for about 91% in domestic exports and giyeoha,'1 billion last year, the export trade of the day Top of the award and has won the honor. Export growth next year through continued sales growth may expect this to take place. Production of high quality back end, enabling this growth has continued, and pride, I try to come as the global levels of cGMP Verna bayiohtek maintain Korea, to secure the best production of the vaccine will work.

    Verna Primary family
    Verna in the domestic big 3 family (B-type hepatitis, A, hepatitis, flu) was released, hepa box - Jean ® 'and' hepa box - Jean ® tiepeu 'products, including the 6 (hepa box - Jean ® , hepa box - Jean ® tiepeu, yipaksal ® Verna, inpeulreksal ® V, surface antigen influenza vaccine ®, Grip Box II ®) inba is introduced in the country. Dual 'hepa box - Jean ®', 'hepa box - Jean ® tiepeu', 'kwinbaksem' direct development in Korea, and around the world for more than 90 countries and international health organizations are suchuldoe. Top of'1 billion export 'of the first class award gongsinin 5 honhapbaek' kwinbaksem (Quinvaxem ®) 'five kinds of the world's first single antigen' bayial 'honhapbaeksin manufactured completely in liquid form, WHO from that require a supply of vaccine, designated as a priority in the world is get attention. 'Kwinbaksem the major pediatric jilbyeongin diphtheria, tetanus, pertussis, B, and hepatitis b cause Meningitis Walter hemopilruseu to prevent influenza. WHO in September of 2006, was acquired prior to verification, 2006, including 10 in the UN and other international health organizations around the world exported in bulk for the world to promote children's health is a vaccine used in the program.
    Verna Korea Major Products ▶ B hepatitis vaccine bayiohtek hepa box - Jean ® (Hepavax-Gene ®) ▶ B hepatitis vaccine, hepa box - Jean ® tiepeu (Hepavax-Gene ® TF) ▶ 5 go at once to prevent disease, 5 honhapbaeksin kwinbaksem ® (Quinvaxem) ▶ A vaccine for hepatitis yipaksal ® Verna (Epaxal ® Berna) ▶ influenza (flu) vaccine inpeulreksal ® V (Inflexal ® V) ▶ typhoid vaccine bibotipeu (Vivotif ®) ▶ cholera vaccine dyukoral (Ducoral ®) * Total of 7 Products hepa box - Jean, hepa box - Jean tiepeu, kwinbaksem three products, including research and development in South Korea's production and sale.
    www.bernabiotech.co.kr/home/bbs/board...
  10. maxen 2 februari 2009 10:49
    Mijn favoriete stukje:
    quote:

    flosz schreef:

    ...
    Q. The goal of sales growth this year bayiohtek Verna?
    A. The first desk, the company does not tell you about the exact sales yesangaek widely awesome and we appreciate your patience, please.
    ...
    Keurige manieren. Dit stukje zou bij elke vage Crucell PB moeten staan bv.:

    We just closed our biggest deal ever, for which we cannot disclose anything, and we appriciate your patience, please.

    Of deze:

    We are in friendly talks with several interested parties and cannot disclose anything for the coming several months, and we appreciate your patience, please.

    Klinkt al een stuk vriendelijker, istniet? ;-)
  11. [verwijderd] 5 februari 2009 10:31
    GSK loses in a invalidity lawsuit against Quinbacsem, a five compound mixed vaccine
    GSK lost in a patent invalidity lawsuit of a mixed vaccineThe patent invalidity case raised by GlaxoSmithKline biologicals SA against Berna ..

    December 17th, 2008

    www.pharmakoreana.com/online_search_r...

  13. flosz 8 februari 2009 19:22
    quote:

    gocrucellgo schreef:

    GSK loses in a invalidity lawsuit against Quinbacsem, a five compound mixed vaccine
    GSK lost in a patent invalidity lawsuit of a mixed vaccineThe patent invalidity case raised by GlaxoSmithKline biologicals SA against Berna ..

    December 17th, 2008

    www.pharmakoreana.com/online_search_r...


    Héél mooi go!
  14. [verwijderd] 9 februari 2009 01:37
    De nieuwe Korea fabriek zal een flinke uitbreiding betekenen van de QV-capaciteit. Met de Jong aan de knoppen, met zijn DSM-ervaring (meesters in proces-optimalisatie, zie Percivia!), zal tevens de kans worden aangegrepen om de kostprijs van het productieproces flink terug te dringen.

    Ik houd er daarom rekening mee dat ze daarmee niet alleen op product-kwaliteit, maar ook op kostprijs en productiecapaciteit de Indische concurrentie achter zich zullen kunnen laten.

    Daarmee lijkt de kans groot dat de marktaandeel verliezen in de huidige markten ruimschoots zullen worden overtroffen door extra afzet in nieuwe markten, waaronder India.

    Wat schatten jullie in?
  15. flosz 18 maart 2009 08:39
    Jan-Feb 2009 > Investment > Ombudsman's Office at Work l

    PLANNING AN EXIT
    The Ombudsman is called in to break an impasse after vaccine producer Berna Biotech is presented with an eviction notice
    The rapid pace of myriad aspects of life in Korea never fails to impress even the longest-term foreign residents of the world's 13th largest economy. In fact, the country's development from being counted among the world's poorest nations several decades ago to one of its wealthiest at present can be directly attributed to the Korean bballi-bballior "quickly quickly" temperament. The speed at which even the seemingly impossible becomes possible in Korea can surely be considered a prime factor behind the decision of multinational corporations to invest here.
    One of the world's few high-speed train networks and a prize-winning international airport built on reclaimed land are just two manifestations of Koreans' capacity to accomplishment the monumental in a short space of time. However, as regular readers of the Invest Korea Journal will recall from the September/October 2008 Ombudsman's Office at Work column that featured the plight of foreign and domestic companies located in a planned "new city" zone, finding one's self directly in the path of a Korean development project can quickly become an exercise in headache and frustration, if but only temporarily.
    The background of this issue's Ombudsman's Office at Work is the establishment of yet another subway line in the greater Seoul Metropolitan Area's growing underground transportation network. Line No. 9, running from the satellite city Bundang to the southern Seoul hub of Gangnam Station, will, when completed, cut the commute from start to finish to only 16 minutes.
    It is easy to imagine that, as with other major infrastructure projects, the construction of a subway line would entail a massive and expensive effort by affected businesses and residences to relocate to unaffected areas. For this particular region of Gyeonggi Province, however, such worries were not caused solely by the establishment of the "Bundang Line" but also by a decision by the city of Yongin to build a light rail line that would link Seoul's subway system to the Everland amusement park, South Korea's largest park of its kind and ranked 10th worldwide in 2007 in attendance.

    CRYING FOUL
    One of the companies directly affected by the city of Yongin's plan to develop the light rail system was Green Cross, a pharmaceutical company that had originally entered a strategic alliance with Rhein Biotech of the Netherlands in 2000, which itself was later acquired by vaccine producer Berna Biotech of Switzerland in 2003. For the sake of accuracy, it should be mentioned that all outstanding shares of Berna Biotech were acquired by Crucell N.V. of Leiden, The Netherlands in early 2006, making the new entity the sixth-largest vaccine company in the world.
    A five-year lease agreement between Green Cross and Berna Biotech was made in 2003, allowing Berna Biotech use of nearly one-sixth of the over 60,000-square meter site for production of its pentavalent children's vaccine Quinvaxem(R) for a period of five years, with an option for automatic renewal thereafter. This particular vaccine was sold to The United Nations Children's Fund (UNICEF) and delivered to areas in need by the World Health Organization (WHO). At the time, total sales for the Quinvaxem(R) vaccine had reached 180 billion won.
    Although Berna Biotech Korea, which would become Crucell Berna Biotech Korea in 2007, had been operating its vaccine production facilities for nearly three years from entering into the lease agreement with Green Cross, due to its status as a sublettor, the company itself did not receive formal notification from the city of Yongin in 2006 that a subway station was to be built on the property, thus requiring the tenants to relocate and set up shop elsewhere.
    When finally made aware of the need to vacate the premises by a December 2008 deadline, Berna Biotech Korea cried foul, stating it had never received official notification, and argued that the relocation process would require three-and-a-half years more in the light of time needed to identify a new facility and begin production on their vaccines at the new location. Further frustrating the company was that, if it were forced to move, the vaccine it had been producing would once again have to undergo a testing process -- post-move -- to ensure identical standards were being met. Then, the testing service itself would have to be reevaluated by the WHO, providing the company with yet additional strife.

    BOTH SIDES AT LOGGERHEADS
    Several options made available to Berna Biotech Korea management included compensation from Green Cross and assistance in relocating to the site which Green Cross had chosen as the location of its future factory, an industrial complex in Hwasoon in South Jeolla Province. With the second option rejected due to the area's inaccessibility to Seoul and major transportation routes, as time was the essence rather than money, Berna Biotech Korea took the issue to the courts. Local antagonism was also growing against the foreign company as its unwillingness to move angered a zone development consortium of over 200 individuals from the area and two company shareholders -- one of which was a Green Cross proxy -- which had been formed to finance construction of rail station commercial complex which would include a 50-floor commercial building.
    It should be pointed out that the construction of social overhead capital (SOC) projects in Korea, especially those related to public transport systems, still receive top priority at both the national and local level. Thus, whatever and whomever own facilities and/or land on the site of a planned development project are expected to defer to the requests of the relevant authorities.
    This said, with the sides at loggerheads, however, Dr. Ahn Choong-Yong, Korea's Investment Ombudsman was contacted to try to find a resolution to the dilemma. During a visit to Yongin city government, Dr. Ahn was told that all companies were subject to zoning regulations and this did not exclude Berna Biotech Korea, even in light of its sublettor status. The foreign company was also suspected of holding out in order to get additional compensation from local authorities, a supposition the Ombudsman effectively quashed. A proposal was made by Dr. Ahn, however, that the company be allowed to stay at the site for the specifically desired period of time while construction on the new subway station would go on around it.
    Said the Investment Ombudsman, "As the exact site where the Berna factory was located was destined to become the [subway station's] parking lot, I felt that its completion could be left until the end of the entire project, thus allowing the factory to maintain its status for the remainder of the time it was requesting."

  16. flosz 18 maart 2009 08:40
    AVOIDING A "SECOND LONE STAR"
    Concurrently discussing related issues with representatives of both Green Cross and Berna Biotech Korea, the Investment Ombudsman brought the sides together for three separate meetings. Dr. Ahn made several visits to, and consultations with, officials at Yongin city government regarding how to entertain the extension request of Berna Biotech Korea. The Investment Ombudsman felt it imperative that the dispute be resolved in a timely manner in order to prevent the company from being demonized and becoming "a second Lone Star," a reference to the witch hunt-like treatment the U.S. Texas-based fund received in Korea following its purchase and plan to sell Korea Exchange Bank, treatment that many foreign investors perceived as being xenophobic in nature.
    Seeing little progress, an initial four-party meeting eventually expanded to include six-parties: Berna Biotech Korea, Green Cross, the Yongin city government, KOTRA, the local land development consortium, and the Ministry of Knowledge Economy. Although Berna Biotech Korea refused to consider relocating to the Hwasoon complex, a proposal was made for a possible move to Incheon Free Economic Zone (IFEZ).
    In mid-October 2008, an agreement was eventually reached to relocate the Berna Biotech production facility to the IFEZ. The construction of the new factory is set to begin soon, and just in time, as according to the company, demand for their children's vaccine is on the rise; production doubled in 2008 compared to the previous year.
    On a related note, Investment Ombudsman Dr. Ahn Choong-Yong was honored at the beginning of December with the Responsible Partner Award, given by the European Union Chamber of Commerce in Korea at their 2008 Korea-EU Industrial Cooperation Day awards ceremony (see Chamber II) for his efforts to assist companies from Europe pursue business in Korea.
    Throughout 2009, the Ombudsman and his team of Home Doctors will continue to assist all foreign-invested companies in need of grievance resolution. He and the Investment Aftercare Service Team can be contacted at 82-2-3460-7635 or on the Internet at [www.i-ombudsman.or.kr].
    By Todd Sample todd@kotra.or.kr
    www.ikjournal.com/InvestKoreaWar/work...
  18. flosz 20 maart 2009 07:40
    Van IV, by donnbonn.

    FEZ tax breaks to arrive faster
    March 20, 2009
    The government is streamlining the process of receiving tax benefits for investing in free economic zones, the Ministry of Knowledge Economy said yesterday.

    Foreign companies within a free economic zone will only have to be evaluated and approved by the free economic zone committee, chaired by Knowledge Economy Minister Lee Youn-ho, to receive the maximum seven-year tax break.

    The law was changed in January to grant foreign investors exemptions from all taxes, from corporate and income taxes to taxes on registration and property, for a maximum of five years. For the following two years, major companies operating inside free economic zones will only have to pay half their taxes.

    To win those benefits, companies will have to meet certain requirements, however.

    For manufacturers, foreign investment must total over $30 million. For tourism-related companies, the investment has to exceed $20 million, while a stake in a logistics company must total at least $10 million.

    To receive the benefits for research facilities, investors must spend more than $2 million and hire more than 10 researchers.

    Previously, even companies operating inside free economic zones had to apply for tax benefits to the government’s foreign investment committee through a separate process.

    Berna Biotech, which is wholly owned by the Dutch vaccine producer Crucell, recently asked the government for the seven-year tax break. The company plans to build a pharmaceutical plant in the Songdo free economic zone in Incheon.

    The free economic zone committee plans to provide the benefits to Berna as swiftly as possible.

    The ministry said the simplified process would stimulate foreign investment in Korea as well as attracting major foreign companies to establish offices in the country.

    By Lee Ho-jeong Staff Reporter [ojlee82@joongang.co.kr]
    joongangdaily.joins.com/article/view....
  19. flosz 22 april 2009 10:24
    Berna Biotech Korea...showing an 81.33% growth from the previous year.

    Multinational companies’ sales grew 14% last year
    GSK, Sanofi, Bayer in the order of sales results

    By Cho Pil-hyun Update : 2009-04-10 8:00:45

    Major multinational companies made an average of 13.79% growth in sales last year, showing an increase by 1.78%P from the average sales growth of 12.01% in 2007. They made excellent business results with growth of 5.46% in business profits, 24.28% in net (ordinary) profits before corporate taxes, and 47.67% in profits for the term.

    The competition among companies was severe last year, so Pfizer that had placed first in sales every year dived to fourth place, and GSK Korea, the third company previously, ranked first. Bayer Korea recorded the highest 84% growth among all drug companies, making a huge jump from eighth to third place.

    Ilganbosa analyzed the audit reports that multinational drug companies presented to the Financial Supervisory Service. According to the analysis, GSK Korea placed first in sales, recording \391.1 billion in 2008 sales with a 9.80% growth from \356.2 billion in 2007. Sanofi-Aventis Korea placed second with \367.3 billion in sales, showing a decrease of 1.63% from the sales of the previous year. Bayer Korea placed third.

    Pfizer (\333.4 billion) placed fourth, followed by Novartis Korea (\306.9 billion), MSD Korea (\285.1 billion), Janssen Korea (\208.9 billion), AZ Korea (\202.8 billion), Berna Biotech Korea (\174.8 billion), and Roche Korea (\164.6 billion). Among them, Berna Biotech Korea is included among ten top companies in sales, showing an 81.33% growth from the previous year, while Abbott Korea was excluded from the top ten grou.

    www.bosa.co.kr/umap/nzine_view.asp?nz...
102 Posts
Pagina: «« 1 2 3 4 5 6 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 920,39 +0,18%
EUR/USD 1,0716 +0,10%
FTSE 100 8.142,42 -0,05%
Germany40^ 18.016,00 +0,08%
Gold spot 2.319,45 -0,57%
NY-Nasdaq Composite 17.688,88 +0,12%

Stijgers

ING
+2,45%
SIGNIF...
+2,36%
ASMI
+1,98%
ASML
+1,65%
Vopak
+1,42%

Dalers

VIVORY...
-8,85%
ALLFUN...
-3,87%
Air Fr...
-2,50%
Avantium
-2,44%
HEIJMA...
-1,78%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!